Our findings warrant follow-up investigations in a larger, longitudinal MSA cohort to address the dynamics of reactive astrogliosis and neuronal cell loss during MSA and PD pathology and to further establish GFAP and NfL as in vivo biomarkers for MSA. This evidence concerns the gene GFAP and Parkinson disease.